GRIN Therapeutics
Operator of a biopharmaceutical company intended to develop precision therapies for pediatric neurodevelopmental disorders caused by mutations in the GRIN genes. The company specializes in assessing t...
Valuation
$445M
Latest known
Share Price
N/A
Total Raised
$275M
Last Round
N/A